ADVENTRX Pharmaceuticals (ANX) Reports In-Line Q3 EPS Loss of $0.13
Tweet
Share
E-mailGet Alerts ANX Hot Sheet
Join SI Premium – FREE
ADVENTRX Pharmaceuticals (NYSE: ANX) reported Q3 EPS of ($0.13), in-line with the analyst estimate of ($0.13).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
- Eltek Ltd (ELTK) Reports Q2 EPS of $0.41
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
